Literature DB >> 20212154

p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication.

Ian G Cannell1, Yi W Kong, Samantha J Johnston, Melissa L Chen, Hilary M Collins, Helen C Dobbyn, Androulla Elia, Theresia R Kress, Martin Dickens, Michael J Clemens, David M Heery, Matthias Gaestel, Martin Eilers, Anne E Willis, Martin Bushell.   

Abstract

The DNA damage response activates several pathways that stall the cell cycle and allow DNA repair. These consist of the well-characterized ATR (Ataxia telangiectasia and Rad-3 related)/CHK1 and ATM (Ataxia telangiectasia mutated)/CHK2 pathways in addition to a newly identified ATM/ATR/p38MAPK/MK2 checkpoint. Crucial to maintaining the integrity of the genome is the S-phase checkpoint that functions to prevent DNA replication until damaged DNA is repaired. Inappropriate expression of the proto-oncogene c-Myc is known to cause DNA damage. One mechanism by which c-Myc induces DNA damage is through binding directly to components of the prereplicative complex thereby promoting DNA synthesis, resulting in replication-associated DNA damage and checkpoint activation due to inappropriate origin firing. Here we show that following etoposide-induced DNA damage translation of c-Myc is repressed by miR-34c via a highly conserved target-site within the 3(') UTR. While miR-34c is induced by p53 following DNA damage, we show that in cells lacking p53 this is achieved by an alternative pathway which involves p38 MAPK signalling to MK2. The data presented here suggest that a major physiological target of miR-34c is c-Myc. Inhibition of miR-34c activity prevents S-phase arrest in response to DNA damage leading to increased DNA synthesis, DNA damage, and checkpoint activation in addition to that induced by etoposide alone, which are all reversed by subsequent c-Myc depletion. These data demonstrate that miR-34c is a critical regulator of the c-Myc expression following DNA damage acting downstream of p38 MAPK/MK2 and suggest that miR-34c serves to remove c-Myc to prevent inappropriate replication which may otherwise lead to genomic instability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212154      PMCID: PMC2851793          DOI: 10.1073/pnas.0910015107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells.

Authors:  Vivienne Tilleray; Constantina Constantinou; Michael J Clemens
Journal:  FEBS Lett       Date:  2006-02-21       Impact factor: 4.124

2.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

Review 3.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

4.  MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.

Authors:  David C Corney; Andrea Flesken-Nikitin; Andrew K Godwin; Wei Wang; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2007-09-06       Impact factor: 12.701

5.  Non-transcriptional control of DNA replication by c-Myc.

Authors:  David Dominguez-Sola; Carol Y Ying; Carla Grandori; Luca Ruggiero; Brenden Chen; Muyang Li; Denise A Galloway; Wei Gu; Jean Gautier; Riccardo Dalla-Favera
Journal:  Nature       Date:  2007-06-27       Impact factor: 49.962

6.  p53-mediated activation of miRNA34 candidate tumor-suppressor genes.

Authors:  Guido T Bommer; Isabelle Gerin; Ying Feng; Andrew J Kaczorowski; Rork Kuick; Robert E Love; Yali Zhai; Thomas J Giordano; Zhaohui S Qin; Bethany B Moore; Ormond A MacDougald; Kathleen R Cho; Eric R Fearon
Journal:  Curr Biol       Date:  2007-07-26       Impact factor: 10.834

7.  A microRNA component of the p53 tumour suppressor network.

Authors:  Lin He; Xingyue He; Lee P Lim; Elisa de Stanchina; Zhenyu Xuan; Yu Liang; Wen Xue; Lars Zender; Jill Magnus; Dana Ridzon; Aimee L Jackson; Peter S Linsley; Caifu Chen; Scott W Lowe; Michele A Cleary; Gregory J Hannon
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

9.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.

Authors:  Nina Raver-Shapira; Efi Marciano; Eti Meiri; Yael Spector; Nitzan Rosenfeld; Neta Moskovits; Zvi Bentwich; Moshe Oren
Journal:  Mol Cell       Date:  2007-05-31       Impact factor: 17.970

10.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.

Authors:  Tsung-Cheng Chang; Erik A Wentzel; Oliver A Kent; Kalyani Ramachandran; Michael Mullendore; Kwang Hyuck Lee; Georg Feldmann; Munekazu Yamakuchi; Marcella Ferlito; Charles J Lowenstein; Dan E Arking; Michael A Beer; Anirban Maitra; Joshua T Mendell
Journal:  Mol Cell       Date:  2007-05-31       Impact factor: 17.970

View more
  98 in total

1.  miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kappaB.

Authors:  Zheng Xu; Shao-Bo Xiao; Peng Xu; Qian Xie; Lu Cao; Dang Wang; Rui Luo; Yao Zhong; Huan-Chun Chen; Liu-Rong Fang
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 2.  Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response?

Authors:  H Christian Reinhardt; Ian G Cannell; Sandra Morandell; Michael B Yaffe
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

Review 3.  MicroRNAs: new players in the DNA damage response.

Authors:  Hailiang Hu; Richard A Gatti
Journal:  J Mol Cell Biol       Date:  2010-12-23       Impact factor: 6.216

4.  P53 is required for the developmental restriction in Müller glial proliferation in mouse retina.

Authors:  Yumi Ueki; Mike O Karl; Samuel Sudar; Julia Pollak; Russell J Taylor; Kati Loeffler; Matthew S Wilken; Sara Reardon; Thomas A Reh
Journal:  Glia       Date:  2012-07-06       Impact factor: 7.452

5.  A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Authors:  Karl A Merrick; Sandra Morandell; Chang-Qi Zhu; Ian G Cannell; Christian J Braun; Robert A Grant; Eleanor R Cameron; Ming-Sound Tsao; Michael T Hemann; Michael B Yaffe
Journal:  Cancer Cell       Date:  2015-11-09       Impact factor: 31.743

6.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

Review 7.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

8.  Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5p.

Authors:  Xiaojian Xu; Shumin Wang; Juan Liu; Dou Dou; Limei Liu; Zhengju Chen; Liping Ye; Huixia Liu; Qiong He; J Usha Raj; Yuansheng Gao
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

9.  Non-coding RNAs in DNA damage response.

Authors:  Yunhua Liu; Xiongbin Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  Requirement for dicer in survival of proliferating thymocytes experiencing DNA double-strand breaks.

Authors:  Brenna L Brady; Levi J Rupp; Craig H Bassing
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.